Psomagen, Inc.

A950200

KR8840150005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
4,755 ^KRW	+0.63%		+0.85%	-6.76%

03-18	The Global Parkinson's Genetics Program and Psomagen Inc. Make Agreement with Goal to Transform Parkinson's Disease Genetics Research and Patient Outcomes	CI
2023	Psomagen Announces the Launch of Spatial Biology Services for 10X Genomics Xenium??	CI

Psomagen, Inc. has filed an IPO.

November 08, 2019 at 05:00 am

Psomagen, Inc. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: KRW 13300 to KRW 17200 Transaction Features: Sponsor Backed Offering

Latest news about Psomagen, Inc.

The Global Parkinson's Genetics Program and Psomagen Inc. Make Agreement with Goal to Transform Parkinson's Disease Genetics Research and Patient Outcomes	03-18	CI
Psomagen Announces the Launch of Spatial Biology Services for 10X Genomics Xenium??	12/09/23	CI
Psomagen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Psomagen, Inc. Launches New Brand Kean Health	15/11/21	CI
Psomagen, Inc. Announces Executive Appointments	15/11/21	CI
Psomagen, Inc. Is Partnering with Olink Proteomics, Enabling Unprecedented Multi-Omics Clinical Studies	11/11/21	CI
Psomagen, Inc. Launches New Vaginal Microbiome Study	29/09/21	CI
Psomagen Inc. Expands Its COVID-19 Diagnostic Services to Include At-Home Saliva Collection Kits	06/07/21	CI
Psomagen, Inc. Expands Precision Genomics Capabilities with 10x Genomics’ Single Cell Sequencing Technologies	23/02/21	CI
Psomagen, Inc. has completed an IPO in the amount of KRW 46.2 billion.	02/07/20	CI
Psomagen and Cell Biotech to Enter into Agreement	21/06/20	CI
Psomagen, Inc. has filed an IPO.	08/11/19	CI
Credian Partners completed the acquisition of an unknown minority stake in Macrogen Corp.	10/02/17	CI
Credian Partners agreed to acquire unknown minority stake in Macrogen Corp for $10 million.	22/09/16	CI

Psomagen, Inc. is an integrative omics solutions and contract laboratory services provider. The Companyâs labs are United States-based and are Clinical Laboratory Improvement Amendments (CLIA) certified and include certified authorization professional (CAP) accredited facilities. Its omics services include Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Sanger Sequencing, Microarray Analysis, Epigenomics Sequencing, Metagenomics Sequencing, Ribonucleic acid (RNA) Sequencing, Single-Cell Sequencing and Biomarker Profiling. It also offers SARS-CoV-2 Variant Sequencing services. The Companyâs Microarray Analysis is a multiplex genomics approach that targets and quantifies specific genes by hybridizing the nucleic acid to a chip and providing an output of genotyping data on a genome-wide scale. Epigenomics is the study of epigenetic changes, such as chromatin assembly, histone modification, and Deoxyribonucleic acid DNA-protein interaction in a cell.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PSOMAGEN, INC.	-6.76%	66.14M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B